MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

Completed
Conditions
Fungal Infection by Site
Interventions
First Posted Date
2008-07-24
Last Posted Date
2014-07-23
Lead Sponsor
CPL Associates
Target Recruit Count
28
Registration Number
NCT00721487
Locations
🇺🇸

CPL Associates,LLC, Buffalo, New York, United States

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

Phase 3
Completed
Conditions
Invasive Candidiasis
Interventions
First Posted Date
2008-06-03
Last Posted Date
2011-05-30
Lead Sponsor
Pfizer
Target Recruit Count
216
Registration Number
NCT00689338
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

Phase 3
Completed
Conditions
Candidiasis, Oral
Interventions
First Posted Date
2008-04-24
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
523
Registration Number
NCT00666185
Locations
🇿🇦

2 Sites, Port Elizabeth, South Africa

🇵🇪

4 Sites, Lima, Peru

🇧🇷

8 Sites, Sao Paulo, Brazil

and more 2 locations

A Study Of Diflucan In Children With Ringworm Of The Scalp

Phase 3
Completed
Conditions
Tinea Capitis
Interventions
First Posted Date
2008-03-27
Last Posted Date
2021-07-16
Lead Sponsor
Pfizer
Target Recruit Count
185
Registration Number
NCT00645242
Locations
🇵🇷

Pfizer Investigational Site, Ponce, Puerto Rico

Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania

Phase 4
Completed
Conditions
Oropharyngeal Candidiasis
Interventions
First Posted Date
2007-11-04
Last Posted Date
2008-05-07
Lead Sponsor
Netherlands Organisation for Scientific Research
Target Recruit Count
220
Registration Number
NCT00553137
Locations
🇹🇿

ART clinic Muhimbili National Hospital/Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania

Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week

Phase 4
Conditions
Pulmonary Candidiasis
First Posted Date
2007-10-02
Last Posted Date
2010-12-14
Lead Sponsor
Capital Medical University
Target Recruit Count
200
Registration Number
NCT00537888
Locations
🇨🇳

Beijing Chaoyang Hospital,Affiliate of Capital Medical University, Beijing, Beijing, China

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

First Posted Date
2007-07-04
Last Posted Date
2011-10-03
Lead Sponsor
Pfizer
Target Recruit Count
282
Registration Number
NCT00496197
Locations
🇰🇷

Pfizer Investigational Site, Seoul, Korea, Republic of

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Phase 3
Completed
Conditions
Coccidioidomycosis
Interventions
First Posted Date
2007-01-18
Last Posted Date
2017-04-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00423267

Diabetes Mellitus and Vulvovaginal Candidiasis

Phase 3
Completed
Conditions
Diabetes Mellitus
Vulvovaginal Candidiasis
Interventions
First Posted Date
2006-07-18
Last Posted Date
2008-05-22
Lead Sponsor
Indian Council of Medical Research
Target Recruit Count
100
Registration Number
NCT00353561
Locations
🇮🇳

Dr Ravinder Goswami, Delhi, India

Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients

Phase 4
Withdrawn
Conditions
Sepsis
Candidiasis
Interventions
First Posted Date
2006-03-20
Last Posted Date
2024-06-14
Lead Sponsor
Kyoto University
Registration Number
NCT00304772
Locations
🇯🇵

Department of Clinical Laboratory Medicine, Kyoto University Hospital, Kyoto, Japan

© Copyright 2025. All Rights Reserved by MedPath